HIF-Stabilizing Glomerular Disease Therapy for Slower Renal Decline
Find Innovative SolutionsGenerate Solutions
Solution Overview
Problem
Current treatments for glomerular diseases, such as glomerulopathy and glomerulosclerosis, are inadequate in effectively managing symptoms and preventing progression to end-stage renal disease, and there is a need for more targeted therapeutic approaches.
Innovation Solution
The use of compound of formula (Ia) or its pharmaceutically acceptable salts, alone or in combination with other therapeutic agents like Factor B inhibitors or Angiotensin II receptor antagonists, to stabilize hypoxia-inducible factors (HIFs) and reduce inflammation, thereby slowing the progression of glomerular diseases.
Engineering Contradictions & Design Principles
Engineering Contradiction Analysis
1Reliability
If standard therapy (steroids or anti-infective agents) is used to treat glomerular diseases, then inflammation is suppressed, but disease progression to end-stage renal disease is not effectively prevented
Solution Approach 1:
The patent changes the therapeutic parameter from traditional anti-inflammatory agents to PHD inhibitors that stabilize HIF-1α. This parameter change enables dual benefit: suppressing inflammation while simultaneously preventing disease progression through HIF-1α mediated protection against oxidative stress and fibrosis, thereby resolving the contradiction between inflammation control and disease prevention
Solution Approach 2:
The patent introduces HIF-1α stabilization as an intermediary mechanism between inflammation suppression and disease progression prevention. By stabilizing HIF-1α, the compound acts as a mediator that simultaneously achieves both inflammation control and protection against renal fibrosis and oxidative stress, enabling reliable disease progression prevention while maintaining inflammation suppression
2Reliability
If PHD inhibitors are used to stabilize HIF and increase EPO secretion, then anemia is reduced and oxygen delivery to kidney is improved, but the mechanism for direct anti-inflammatory effect is not fully established
Solution Approach 1:
The patent applies multi-functionality by demonstrating that HIF-1α stabilization serves multiple purposes simultaneously: (1) increases EPO secretion to treat anemia, (2) improves oxygen delivery to the kidney, (3) suppresses inflammation through HIF-1α mediated mechanisms, and (4) prevents disease progression. This universal mechanism resolves the contradiction by showing that a single intervention achieves both oxygen delivery improvement and inflammation control
3Quantity of substance
If chronic hypoxia is present, then anemia develops, but it also accelerates glomerulopathy and glomerulosclerosis progression
Solution Approach 1:
The patent applies preliminary action by stabilizing HIF-1α before severe glomerular damage occurs. This preliminary stabilization prevents the harmful effects of hypoxia-driven inflammation and oxidative stress, thereby protecting glomerular function while simultaneously improving oxygen delivery. The compound acts preventively rather than reactively, resolving the contradiction between oxygen delivery and glomerular function preservation
Applied Scientific Principles
This section explains which scientific principles are used to turn an abstract innovation direction into a practical engineering solution.
Function Achieved in This Case
The compound of formula (Ia) effectively stabilizes HIFs, reducing inflammation and oxidative stress, leading to improved kidney function and a decrease in proteinuria, thereby delaying disease progression and improving clinical symptoms.
Implementation Method 1
Inhibition of PHD can stabilize HIF thus increasing the availability of HIF at the site of inflammation
Implementation Method 2
Activation of HIF prevents nephropathy and ischemia-reperfusion injury
Implementation Method 3
HIF has been reported to regulate nuclear factor-κB (NF-κB) and extracellular signal-regulated kinase (ERK) mediated inflammatory pathways
Implementation Method 4
HIF has been reported to regulate nuclear factor-κB (NF-κB) and extracellular signal-regulated kinase (ERK) mediated inflammatory pathways
Implementation Method 5
Desidustat treatment reduced IL-6 and IL-1β levels in ischemia condition. These inflammatory markers were increased in renal dysfunction either nephropathy or nephritis. It also decreases SOD and MDA thus decreases oxidative stress
Data Source
AI summary
The present invention relates to the development of therapeutic compound for the treatment of glomerular diseases. Specifically, present invention relates to use of compound of formula (Ia) or its pharmaceutically acceptable salt or combination thereof or pharmaceutical composition thereof for the treatment of glomerular diseases.